Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for renal protection during abdominal aortic surgery
PACTR202402909858685Phase 4Not yet recruiting
- Sponsor
- Kafr El Sheikh Pharmaceutical Industries
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dexmedetomidine in acute kidney failure (AKF) (2 arms), sponsored by Kafr El Sheikh Pharmaceutical Industries. Primary endpoint: Urinary kidney injury molecule-1. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on PACTR202402909858685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202402909858685.